We’ve recently updated our valuation analysis.

3SBio Valuation

Is 1530 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1530?

Other financial metrics that can be useful for relative valuation.

1530 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.9x
Enterprise Value/EBITDA9.4x
PEG Ratio6.7x

Price to Earnings Ratio vs Peers

How does 1530's PE Ratio compare to its peers?

The above table shows the PE ratio for 1530 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average52.2x
6826 Shanghai Haohai Biological Technology
29.8x24.7%HK$18.6b
775 CK Life Sciences Int'l. (Holdings)
60.3xn/aHK$7.7b
1061 Essex Bio-Technology
6.9x15.0%HK$2.2b
9995 RemeGen
111.7x60.6%HK$46.5b
1530 3SBio
11x1.6%HK$21.6b

Price-To-Earnings vs Peers: 1530 is good value based on its Price-To-Earnings Ratio (11x) compared to the peer average (52.2x).


Price to Earnings Ratio vs Industry

How does 1530's PE Ratio compare vs other companies in the Asian Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a45.9%
n/an/an/a

Price-To-Earnings vs Industry: 1530 is good value based on its Price-To-Earnings Ratio (11x) compared to the Asian Biotechs industry average (37.4x)


Price to Earnings Ratio vs Fair Ratio

What is 1530's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1530 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio11x
Fair PE Ratio12.3x

Price-To-Earnings vs Fair Ratio: 1530 is good value based on its Price-To-Earnings Ratio (11x) compared to the estimated Fair Price-To-Earnings Ratio (12.3x).


Share Price vs Fair Value

What is the Fair Price of 1530 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 1530 (HK$8.86) is trading below our estimate of fair value (HK$11.09)

Significantly Below Fair Value: 1530 is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1530 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentHK$8.86
HK$7.90
-10.8%
16.9%HK$11.08HK$5.94n/a11
Jan ’24HK$8.30
HK$7.26
-12.6%
19.3%HK$10.76HK$5.50n/a10
Dec ’23HK$8.27
HK$7.05
-14.8%
19.7%HK$10.49HK$5.26n/a10
Nov ’23HK$5.80
HK$6.88
+18.6%
20.3%HK$10.47HK$5.25n/a10
Oct ’23HK$5.57
HK$6.86
+23.1%
20.4%HK$10.47HK$5.25n/a10
Sep ’23HK$5.32
HK$7.35
+38.1%
20.9%HK$10.91HK$5.47n/a10
Aug ’23HK$5.10
HK$8.15
+59.7%
19.7%HK$11.41HK$6.02n/a10
Jul ’23HK$6.24
HK$8.34
+33.6%
19.0%HK$11.67HK$6.80n/a9
Jun ’23HK$5.76
HK$8.33
+44.6%
19.5%HK$11.70HK$6.52n/a9
May ’23HK$5.55
HK$8.15
+46.8%
14.8%HK$10.00HK$6.72n/a8
Apr ’23HK$6.45
HK$8.79
+36.3%
20.2%HK$12.60HK$6.80n/a9
Mar ’23HK$6.30
HK$9.20
+46.1%
19.1%HK$12.67HK$7.30n/a10
Feb ’23HK$6.15
HK$10.30
+67.4%
27.3%HK$17.35HK$7.22n/a11
Jan ’23HK$6.50
HK$10.44
+60.6%
24.5%HK$17.33HK$8.00HK$8.3012
Dec ’22HK$6.62
HK$10.44
+57.7%
24.3%HK$17.26HK$7.98HK$8.2712
Nov ’22HK$7.00
HK$10.39
+48.4%
23.5%HK$17.20HK$7.95HK$5.8013
Oct ’22HK$7.65
HK$10.29
+34.5%
23.3%HK$17.06HK$7.41HK$5.5716
Sep ’22HK$8.60
HK$10.24
+19.1%
23.1%HK$17.04HK$7.40HK$5.3216
Aug ’22HK$6.47
HK$10.65
+64.7%
21.7%HK$16.93HK$7.35HK$5.1015
Jul ’22HK$9.60
HK$10.70
+11.5%
21.6%HK$17.26HK$7.39HK$6.2415
Jun ’22HK$9.28
HK$10.63
+14.5%
21.6%HK$17.32HK$7.41HK$5.7616
May ’22HK$7.36
HK$10.57
+43.6%
21.7%HK$17.14HK$7.34HK$5.5516
Apr ’22HK$7.00
HK$9.95
+42.2%
13.3%HK$12.14HK$7.28HK$6.4514
Mar ’22HK$8.03
HK$11.30
+40.7%
12.0%HK$15.10HK$9.01HK$6.3014
Feb ’22HK$7.62
HK$11.26
+47.8%
11.5%HK$15.06HK$8.98HK$6.1515
Jan ’22HK$7.07
HK$11.91
+68.5%
17.0%HK$18.38HK$9.85HK$6.5016

Analyst Forecast: Target price is lower than the current share price.


Discover undervalued companies